Filing Flows › Prelude Therapeutics (PRLD) › Q1 2026
Prelude Therapeutics (PRLD) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Prelude Therapeutics (PRLD) reported revenue of $4.6M for the first quarter 2026 (Q1 2026) and -19% from the quarter before. Operating margin was -309.5%, net loss $10.4M (226.7% of revenue).
Prelude Therapeutics, Q1 2026: revenue $4.6M, operating margin -309.5%, net loss $10.4M, operating cash flow −$21.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.6M | -19% | — |
| Operating profit | −$14.2M | — | — |
| Net earnings | −$10.4M | — | — |
| Operating cash flow | −$21.7M | -194% | — |
What changed
Revenue was $4.6M in Q1 2026, down 19% from the previous quarter.
Operating costs exceeded revenue by $14.2M, an operating margin of -309.5%. The quarter ended with a net loss of $10.4M, narrower than the previous quarter's $16.5M loss. Non-operating items added $3.8M, -37% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$21.7M. Non-cash charges added back $391K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $13.7M.
Questions
What was Prelude Therapeutics' revenue in the first quarter 2026?
Prelude Therapeutics (PRLD) reported revenue of $4.6M for the first quarter 2026 (Q1 2026) and -19% from the quarter before.
Was Prelude Therapeutics profitable in the first quarter 2026?
Operating loss was $14.2M (-309.5% of revenue) and net loss $10.4M.